Physician profile
Lynn Rawson
NPI 1285836023
$13,803.76
in general payments reported to CMS, 2019-2025
21 companies · $1,181 in 2025
The $1,181 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,113 · 2020: $319 · 2021: $476 · 2022: $5,313 · 2023: $688 · 2024: $3,713 · 2025: $1,181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,266 · Food and Beverage: $2,308 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,265.98 |
| Food and Beverage | $2,307.97 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $12,629.19 | 2019-2025 | Da Vinci Surgical System |
| Davol INC. | $375.32 | 2020-2025 | Phasix Mesh |
| Conmed Corporation | $162.50 | 2019-2021 | |
| Tela Bio, INC. | $159.90 | 2022-2024 | Ovitex 2s, Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Amneal Pharmaceuticals LLC | $64.09 | 2022-2023 | Rytary |
| Jazz Pharmaceuticals INC. | $48.89 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.30 | 2022-2023 | Ofev |
| Lundbeck LLC | $41.24 | 2022-2023 | Vyepti |
| Abbott Laboratories | $39.04 | 2022-2023 | Freestyle Libre 3 |
| Argenx US, INC. | $28.43 | 2022 | |
| Stryker Corporation | $27.69 | 2023 | Neuroform Atlas |
| Csl Behring | $25.34 | 2023 | Hizentra |
| Insulet Corporation | $24.52 | 2024 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $20.93 | 2023 | |
| Merck Sharp & Dohme LLC | $19.34 | 2023 | Recarbrio, Zerbaxa |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $18.84 | 2023 | Mavenclad |
| Boston Scientific Corporation | $18.09 | 2019 | |
| Novo Nordisk INC | $17.38 | 2022 | |
| Ucb, INC. | $15.95 | 2023 | Briviact |
| Mdd US Operations, LLC | $13.73 | 2023 | Apokyn |
| Neurocrine Biosciences, INC. | $11.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Rawson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.